Hikma Pharmaceuticals has entered into an exclusive agreement to co-develop with UK-based Arecor an undisclosed, ready-to-use injectable hybrid for the US market. And the two companies are exploring further opportunities to collaborate.
Under the terms of the royalty-based agreement struck by the London-listed company’s Hikma Pharmaceuticals USA affiliate, Hikma plans next year to make a filing under through the US Food